Brand name- Erlocip
Manufacturer- Cipla pharma
Dosage form- Tablet
Route of Administration- oral
Strength- 100, 150mg
Indication- non-small cell lung cancer (NSCLC) and pancreatic cancer.
Storage- Store at room temperature (10-30°C)
Class of drug- Kinase inhibitor
It is study of drug effects and what the medicine does to the body
It inhibits the intracellular phosphorylation of tyrosine kinase associated with epidermal growth factor (EGFR). As the specificity of inhibition with respect to other tyrosine kinase receptors has not been fully characterized. EGFR is also expressed on the cell surface of normal cells and cancer cells
Study of what body does to the medicine. Erlocip is around 60% absorbed after administration into the body and its bioavailability is increased by food to almost100%. Its half-life is 36 hours and it is cleared majorly by the CYP3A4 enzyme present in the body.
Minimum effect concentration (MEC)
Minimum concentration of medicine in the blood required for producing the therapeutic effects. Its predefined therapeutic MEC is (0.8μg/ml)
Minimum toxic concentration (MTC)
Minimum concentration of medicine in blood above which toxic or adverse effects are precipitated. Its MTC is 1.25μg/ml
Bioavailability rate of Erlocip
After oral administration, the medicine archived approximately 60% bioavailability, with the administration with food enhancing bioavailability to upwards of 100%
The shelf life of Erlocip
Shelf life is the time period over which the concentration of the active medicinal ingredient in the formulation lowers by 10 percent from its value at the time of manufacture.
Erlocip 150mg- 30 Months
Erlocip 100mg- 2 Years
Mechanism of Action
It belongs to a class of medications called kinase inhibitors. It works by blocking the action of abnormal protein that signals cancer cells to multiply. This in turn helps to slow or inhibit the spread of cancer cells
Which disease area
Non-small cell lung cancer (NSCLC) and pancreatic cancer
Erlonat 150mg Tablet by NATCO.
Erlotib 150mg Tablet by Intas.
Zyceva 150mg Tablet by Zydus.
Erleva 100 mg/150 mg by Glenmark.
Common side effects
- Abdominal pain
- Bone pain
- Muscle pain
- Stomatitis (Inflammation of the mouth)
- Weight loss
Serious side effects Erlocip
Fatigue, loss of appetite, partial hair loss, diarrhea, mouth sores, vomiting, rashes, weight loss, dry skin, eye irritation, weight decrease, infection, edema, pyrexia, and constipation, bone pain, dyspnea, stomatitis and myalgia.
Dosage of Erlocip
If the patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose
Get the emergency medical treatment and contact your physician
Warnings of Erlocip
General warning and precautions
The medicine causes skin rash, dryness, or other irritation. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.
Stop using skin products that cause dryness or irritation, such as acne medications, harsh soaps or skin cleansers, or skin products that have alcohol.
It is usually taken on an empty stomach once a day, at least 1 hour before or 2 hours after eating a meal or snack. Take erlocip at around the same time every day.
Consult your doctor before taking this medicine, if you:
Are allergic to ERLOCIP 150MG, or any of the ingredients of this medicine or having a severe liver disease or severe kidney disease
If one uses contact lenses and/or have a history of eye problems such as severe dry eyes
Interactions of Erlocip
Gastrointestinal Diseases (especially peptic ulcer diseases)
Eye disorder (primary keratitis, ulcerative keratitis, conjunctivitis, etc)
Hepatic impairment (extreme caution in patient suffering from liver diseases
1. Alcohol interaction
Alcohol interaction is unknown, consult your doctor
2. Food interaction
The patient should also avoid grapefruit and grapefruit juice while taking the medicine. Food and grapefruit raise the levels of erlocip in your body and lead to increased side effects.
Contraindications of Erlocip
It includes Hypersensitivity